October 20, 2020

AccessDX partners with Trinitas on Innovative COVID-19 Biomarker Risk Assessment Program

​

HOUSTON, TX and WILMINGTON, DE - AccessDX Laboratory (“AccessDX”), a national provider of advanced laboratory diagnostics, today announced a partnership with Trinitas Global (“Trinitas”) to launch an innovative investigational COVID-19 biomarker risk assessment program.  This partnership will utilize a combination of advanced biomarker research, data science, and diagnostic panels to proactively identify patients with a high risk of a severe immune response to a COVID-19 infection. 

​

As many as 1 in 5 positive COVID-19 individuals will require hospitalization or advanced care, and these cases are currently forecasted by the CDC to result in as up to 5,700 new hospitalizations per day through November 2020.  While there are few reliable methods to identify patients likely to suffer from a severe COVID infection, severe cases have been correlated to a hyperactive immune response to the virus (also referred to as a cytokine storm).  Hyperactive immune responses can impact multiple systems and organs within the body, including the potential for Acute Respiratory Distress Syndrome (ARDS) which carries a mortality rate in COVID-19 patients of up to 50%.  

 

Biomarker risk assessment toolsets and supporting solutions in development by Trinitas will be used to help identify and mitigate potential cases of hyperactive immune response to COVID-19 - potentially before a patient is even exposed to the virus.  This may lead to the use of advanced infection protection protocols, targeted therapies, and improved clinical outcomes for these patients.  

 

The Trinitas partnership will leverage the experience and scale of AccessDX as proven through the ongoing response to COVID-19.  AccessDX has now helped thousands of municipalities, health systems, and care facilities gain access to fast, high quality COVID-19 PCR testing, compliance reporting, and end-to-end digital workflows.  Diagnostic solutions from AccessDX will be able to support Trinitas biomarker risk assessment programs in both research environments and at clinical scale.

 

“We’re very pleased to announce this foundational partnership with AccessDX,” said Paul McConnell, Managing Member of Trinitas.  “Our core mission is to apply our research in immune response to help protect those who are most vulnerable among us, and arm clinical professionals with actionable information to help stem the destructive forces of this pandemic,” added McConnell.   

 

Existing AccessDX clients who wish to receive more information on the investigational biomarker risk assessment program can contact their dedicated Client Success team member, or contact covid@accessdxlab.com.

​

About AccessDx Laboratory:  AccessDX Laboratory is a CLIA-certified, CAP-accredited, and NYCQ diagnostic laboratory dedicated to providing clinical insights that improve patient outcomes.  AccessDX diagnostic solutions include pharmacogenomic (PGX) testing, cancer genomic (CGX) testing, respiratory pathogen panels, and a wide range of other clinical laboratory services.  AccessDX diagnostics are currently trusted by thousands of clinical providers in health systems nationwide.  For more information, please visit www.accessdxlab.com.

​

About Trinitas Global:  Trinitas is a data science and research company dedicated to preventative biomarker analysis.  The foundational technology and supporting research of the Trinitas risk assessment toolset uses multiple patient biomarkers to predict the likelihood of adverse immune response for patients impacted by COVID-19, with broader applicability to a range of autoimmune disorders.  For more information, please contact 302-225-7908 or contact info@trinitas.global. 

​